LUNG DEPOSITION OF FENOTEROL AND FLUNISOLIDE DELIVERED USING A NOVEL DEVICE FOR INHALED MEDICINES - COMPARISON OF RESPIMAT WITH CONVENTIONAL METERED-DOSE INHALERS WITH AND WITHOUT SPACER DEVICES
Sp. Newman et al., LUNG DEPOSITION OF FENOTEROL AND FLUNISOLIDE DELIVERED USING A NOVEL DEVICE FOR INHALED MEDICINES - COMPARISON OF RESPIMAT WITH CONVENTIONAL METERED-DOSE INHALERS WITH AND WITHOUT SPACER DEVICES, Chest, 113(4), 1998, pp. 957-963
Citations number
29
Categorie Soggetti
Respiratory System","Cardiac & Cardiovascular System
Study objectives: To compare lung deposition of fenoterol or flunisoli
de administered from a novel, multidose inhalation device delivering l
iquid droplets (RESPIMAT; Boehringer Ingelheim Ltd; Bracknell, UK) or
from conventional metered-dose inhalers (MDIs) with and without spacer
s. Design: Two randomized, three-way crossover studies. Setting: Clini
cal research laboratory. Participants: Healthy, nonsmoking volunteers.
Interventions: Ln one study, radiolabeled aerosols of fenoterol from
the RESPIMAT device and from a conventional MDI with or without an Aer
ochamber spacer (Trudell Medical; London, Ontario Canada). In the seco
nd study, radiolabeled aerosols of flunisolide from a RESPIMAT device,
from a RESPIMAT device modified by inclusion of a baffle/impactor in
the mouthpiece, and from a conventional MDI with an Inhacort spacer (B
oehringer Ingelheim; Ingelheim, Germany). Measurements and results: As
sessment of the deposition of fenoterol or flunisolide in the lung and
oropharynx using gamma scintigraphy. Safety was assessed based on rep
orted adverse effects and spirometry (FEV1, FVC, and peak expiratory n
ow rate) to detect any paradoxical bronchoconstriction. The RESPIMAT d
evice delivered significantly more fenoterol to the lungs than either
an MDI alone or an MDI with Aerochamber (39.2% vs 11.0% and 9.9% of me
tered dose, respectively; p<0.01). Oropharyngeal deposition of fenoter
ol from the new device was lower than that from the MDI (37.1% vs 71.7
%, respectively; p<0.01). The RESPIMAT device deposited significantly
more flunisolide in the lungs compared with MDI plus spacer (44.6% vs
26.4%, respectively; p<0.01), while resulting in similar oropharyngeal
deposition (26.2% vs 31.2%, respectively). Introduction of a baffle i
nto the RESPIMAT system reduced lung deposition of flunisolide to 29.5
%, and oropharyngeal deposition to 7.8% (p<0.01). Conclusion: The RESP
IMAT device may prove to be an effective alternative to MDIs for the a
dministration of inhaled bronchodilators and corticosteroids. The high
lung deposition and low oropharyngeal deposition may lead to improved
efficacy and tolerability of inhaled medications, especially corticos
teroids.